SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

XRP is under pressure amid a broader crypto selloff, with traders focusing on its continued weakness and difficulty sustaining rebounds. Bearish posts blame dilution, Ripples tokenomics, and limited direct demand for XRP, while bullish traders view the decline as a buying opportunity and argue that adoption could support the token over the long term.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

Anticipation around Compass Pathways completing its rolling NDA submission for COMP360, its investigational psilocybin therapy for treatment-resistant depression, is driving attention, with traders focused on the expected Q4 filing and expedited FDA review. Bullish holders see the regulatory milestone and commercial-readiness efforts as near-term catalysts, while others are frustrated by the delay and cautious management comments and remain concerned about approval uncertainty and volatile biotech-sector trading.

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010 and is headquartered in Novato, CA.

Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc

Ultragenyxs recent FDA approvals of the gene therapies FAYUVI and GENGLYCOS, along with agreements to sell the resulting priority review vouchers, dominate discussion as potential support for its cash position and 2027 profitability goal. Bulls see the developments as underappreciated, while others are frustrated by the stocks muted, volatile response and want clearer evidence of launch sales and cost reductions.

RTX Corp. is an aerospace and defense company, which engages in the provision of aerospace and defense systems and services for commercial, military, and government customers. It operates through the following segments: Collins Aerospace Systems (Collins), Pratt and Whitney, Raytheon Intelligence and Space (RIS), and Raytheon Missiles and Defense (RMD). The Collins segment manufactures and sells aero structures, avionics, interiors, mechanical systems, mission systems, and power controls. The Pratt and Whitney segment includes the design and manufacture of aircraft engines and auxiliary power systems for commercial, military, and business aircraft. The RIS segment is involved in the development of sensors, training, and cyber and software solutions. The RMD segment offers end-to-end solutions to detect, track, and engage threats. The company was founded in 1922 and is headquartered in Arlington, VA.

RTX Corp

Raytheon Technologies Corporation

RTXs quarterly earnings beat and raised full-year outlook, supported by strong demand and a record backlog, dominate the discussion. Traders broadly praise the results but are frustrated that the shares have weakened or failed to rally in response.

Newmont Corp. engages in the exploration and acquisition of gold properties, containing copper, silver, lead, zinc or other metals. It operates through the following geographical segments: Papua New Guinea, Australia, Ghana, Suriname, Argentina, Peru, Mexico, Canada, and U.S. The company was founded by William Boyce Thompson on May 2, 1921 and is headquartered in Denver, CO.

Newmont Corp

Newmonts quarterly results beat expectations, but shares are under pressure as traders focus on cost inflation, project spending and risks at key mines; a broker downgrade has added to the selling. Bulls point to improved cost guidance, strong cash generation and exposure to gold, while others question whether those positives offset the outlook concerns.

Interactive Brokers Group, Inc. is an investment holding company, which engages in broker or dealer and proprietary trading businesses. It offers custody and service accounts for hedge and mutual funds, exchange-traded funds, registered investment advisors, proprietary trading groups, introducing brokers, and individual investors. The company was founded by Thomas Pechy Peterffy in 1977 and is headquartered in Greenwich, CT.

Interactive Brokers Group Inc - Ordinary Shares - Class A

Interactive Brokers Group Inc 

Interactive Brokers Q3 results are the main focus: traders note growth in client balances and net interest income alongside softer trading activity, and debate whether expansion can offset rising competition. The stocks muted, negative reaction despite the dividend increase has disappointed some investors, while others view the business fundamentals as strong.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

Traders are focused on CRISPR Therapeutics CTX310 Phase 1b data presentation at the AHA meeting, which they see as an important test of in vivo gene editing for severe hypertriglyceridemia. Some expect the readout to validate the cardiovascular pipeline, while others remain skeptical after prolonged range-bound trading and are uneasy about the CFO transition.

Sony Group Corp. engages in the development, design, manufacture, and sale of electronic equipment, instruments, devices, game consoles, and software for consumers, professionals and industrial markets. It operates through the following segments: Game and Network Services, Music, Pictures, Entertainment Technology & Services, Imaging and Sensing Solutions, Financial Services, and Others. The Game and Network Services segment deals with gaming machines, software and network services. The Music segment produces and publishes music and provides image media platforms. The Pictures segment handles film production, television program creation, and media networks. The Home Entertainment and Sound segment offers LCD televisions, home audio, Blu-ray Disc players and recorders, and memory-based portable audio devices. The Imaging and Sensing Solutions segment includes the image sensors business. The Financial Services segment manages the life insurance and non-life insurance operations and banking business. The Others segment consists of various operating activities, including the disc manufacturing and recording media businesses. The company was founded by Akio Morita and Masaru Ibuka on May 7, 1946 and is headquartered in Tokyo, Japan.

Sony Group Corporation - ADR

Sony Group Corporation

Sonys plan to stop producing physical PlayStation game discs is fueling debate: critics warn the digital-only shift could alienate customers and push players toward PC, while supporters argue it may lower costs and improve margins. Traders are also weighing that backlash against Sonys broader business and image-sensor growth prospects.

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Googles reported magic-state quantum breakthrough has renewed attention across the sector, with traders speculating that Infleqtion could benefit from its neutral-atom technology. Optimism is tempered by the stocks steep decline and broader risk-off pressure, while recent analyst coverage has drawn mixed reactions.

Vanguard Index Funds - Vanguard Morningstar Total Stock Market ETF

Vanguard Total Stock Market ETF

VTI is part of a broad debate over U.S. market risk, with traders warning that AI-heavy valuations, inflation, oil and interest rates could pressure stocks. Others favor the ETFs diversified, low-cost exposure and advocate staying invested or adding through dips.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Palatin Reports Fiscal Year 2026 Financial Results and Provides Business Update

Palatin Reports Fiscal Year 2026 Financial Results and Provides Business Update Palatin Reports Fiscal Year 2026 Financial Results and Provides Business UpdatePR NewswirePRINCETON, N.J., Sept. 28, 2026 Programs are focused on rare obesity disorders associated with the melanocortin 4 receptor (MC4R...

Palatin Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update

Palatin Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update Palatin Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update PR Newswire...

Palatin Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update

Palatin Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update Palatin Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update PR...

Palatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update

Palatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update Palatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update PR...

Palatin Technologies Announces Closing of Upsized $18.2 Million Public Offering with the Full Exercise of the Underwriters' Over-Allotment Option

Palatin Technologies Announces Closing of Upsized $18.2 Million Public Offering with the Full Exercise of the Underwriters' Over-Allotment Option Palatin Technologies Announces Closing of Upsized...

Top 3 Biotech Stocks That Got Retail Street Buzzing Last Week: SMMT, PTN, RXRX

Equity

Positive expectations from key clinical trials, delisting fears and some regulatory changes triggered a flurry of discussions on Stocktwits for these tickers for the week ended April 11, 2025. 

This account has been verified as an official PTN representative.

Verified Account

Palatin Technologies

Palatin reported fiscal Q4 2026 collaboration and license revenue of approximately $300K and net loss of $4.4M; FY2026 revenue was $13.2M and net loss was $8.4M.

Palatin reported $7.5M in cash and substantial doubt about continuing as a going concern, fiscal 2026 operating expenses were $21.9M versus $17.5M, and competition remains a stated risk.

Palatin's selective MC4R compounds demonstrated potent activity without MC1R agonism, a lead peptide demonstrated reductions in food intake and body weight in mice, and PL8177 showed positive Phase 2 proof-of-concept results.

Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin receptor system. Its primary product candidate is marketed under the Vyleesi brand, the trade name for bremelanotide, which is used for the treatment of premenopausal women with acquired, generalized, hypoactive sexual desire disorder (HSDD). The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Princeton, NJ.

Palatin Technologies Inc.

Bullish Sentiment

Summit Therapeutics Inc. (SMMT) - 1100% jump in weekly message volumeThe biopharma company saw a sharp rise in retail chatter on Stocktwits last week, driven by growing analyst optimism around its cancer drug candidate, ivonescimab — a PD-1/VEGF bispecific antibody.&nbsp;Truist, which has a 'Buy' rating and a $35 price target on the stock, called the upcoming survival data from the HARMONi-2 trial of ivonescimab in non-small cell lung cancer one of the year's most anticipated biotech readouts.According to The Fly, Truist said its in-house biostatistics expert believes the study could exceed expectations and demonstrate statistical significance.&nbsp;In a note from late March, Citi said it had developed a "strong conviction" that HARMONi-2 has a 70% chance of delivering a favorable overall survival outcome by the expected year-end update.Meanwhile, Cantor Fitzgerald highlighted co-CEO and chairman Bob Duggan's early exercise of 4 million stock options at $1.58 — roughly four years before expiration — as "quite unusual" and "quite bullish."Retail sentiment for Summit on Stocktwits flipped to 'extremely bullish' from 'neutral' last week, and the stock's year-to-date gains have reached nearly 30%.<figure class="image"><img style="aspect-ratio:1318/316;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_14_at_7_10_22_AM_png_fc435b051c.webp" alt="Screenshot 2025-04-14 at 7.10.22 AM.png" width="1318" height="316"><figcaption>SMMT retail sentiment weekly shift, as of April 11. | source: Stocktwits</figcaption></figure>Palatin Technologies Inc. (PTN) - 600% jump in weekly message volumeCranbury, New Jersey-based Palatin said Thursday that the NYSE American plans to delist its common stock after the company failed to meet the exchange's minimum stockholders' equity requirement by the April 10 deadline.Palatin said it will appeal the decision by April 25 and expects its shares to continue trading on NYSE American during the appeal process.The biopharma company, which develops drugs targeting the melanocortin receptor system, currently runs clinical trials in obesity, dry eye disease, ulcerative colitis, diabetic nephropathy, and other ocular conditions.On Stocktwits, sentiment for Palatin plunged into 'extremely bearish' territory from 'extremely bullish' last week. The stock has lost over 85% this year.<figure class="image"><img style="aspect-ratio:1318/316;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_14_at_7_10_31_AM_png_723d397ddb.webp" alt="Screenshot 2025-04-14 at 7.10.31 AM.png" width="1318" height="316"><figcaption>PTN retail sentiment weekly shift, as of April 11. | source: Stocktwits</figcaption></figure>Recursion Pharmaceuticals Inc. (RXRX) - 500% jump in weekly message volumeShares of Recursion Pharmaceuticals received a big boost last week after the U.S. health regulator unveiled&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rxrx-stock-jumps-after-hours-as-fda-eyes-ai-drug-testing/chfrEfxRbB6">plans</a> to modernize drug testing methodologies.&nbsp;The FDA said it would begin replacing traditional animal testing for monoclonal antibody therapies and other drugs with more "human-relevant" methods, including artificial intelligence (AI) models.This aligns closely with Nvidia-backed Recursion's business model, which uses AI, machine learning, and automation to accelerate drug discovery.&nbsp;On Stocktwits, sentiment for Recursion climbed into the 'extremely bullish' zone from 'bullish' last week, with the stock's year-to-date losses reducing to about 16%.<figure class="image"><img style="aspect-ratio:1318/316;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_14_at_7_34_11_AM_png_ca5ce8aae3.webp" alt="Screenshot 2025-04-14 at 7.34.11 AM.png" width="1318" height="316"><figcaption>RXRX retail sentiment weekly shift, as of April 11. | source: Stocktwits</figcaption></figure>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Summit Therapeutics company logo is seen on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Recursion Pharmaceuticals Inc

Summit Therapeutics Inc

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$5.11
Prev Close	$5.51
Open	$5.44
Dividend Yield	0.00%
50-Day Moving Average	$9.66
Beta	0.05
Avg. Volume	134,867.63
PE Ratio	-63.95

52-Week High	$31.00
52-Week Low	$4.92
Market Capitalization	$9.1M
EPS (Annual)	-$2.96
Price to Book	1.36
Revenue Per Employee	$527,401.24

Feed

News

Sentiment

Earnings

Fundamentals

Info

PTN Fundamentals